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Abstract
Background: Studies have not found that hormonal contraceptive implants adversely affect breastfeeding, but
theoretical concerns exist.
Methods: We reported a case of reduced weight gain in an exclusively breastfed infant in association with
placement of (ENG)-releasing contraceptive implant (Nexplanon) to the FDA Adverse Events Reporting
System (FAERS). We further queried reports to FAERS and reviewed published studies of the ENG implant
during breastfeeding.
Results: A breastfeeding mother received an ENG implant at 4 weeks postpartum. Her infant was exclusively
breastfeeding. One month after implant placement, the infant had lost 145 g, dropping from the 44th percentile
to the 6th percentile for growth. During this period, the mother had not returned to work or decreased frequency
of feeding. During a 2-year period of FAERS reports, we found one other report of reduced milk supply
following ENG implant placement. Among 108 breastfeeding women studied while using the ENG implant,
there was one case of lactation failure. If this were not due to chance, the estimated risk of lactation failure with
the ENG implant would be 0.9% (95% confidence interval 0.2–5.1%).
Conclusion: Given uncertainty regarding the true effect of ENG implants on lactation, it seems prudent for
providers to counsel each woman about a possible effect on milk supply so that she can monitor her infant for
signs of impaired milk transfer. Patient-centered counseling approaches are needed that allow each woman to
assess her own individual tolerance of risk of unplanned pregnancy versus possible risk of lactation failure.
Introduction
Ahealthy 22-year-old African American G1P0 pre-sented in spontaneous labor at 39 weeks 2 days. She pro-
gressed to complete and had an uncomplicated spontaneous
vaginal birth of a 3.316kg male infant with Apgar scores of 9
and 9. During the maternity stay, she exclusively breastfed, and
mother and infant were discharged home on postpartum day 1
with a weight of 3.090kg, 6.8% below birth weight. Mother and
infant presented for pediatric follow-up on postpartum day 4.
The infant’s weight was 3.125 kg, and mother reported breast-
feeding every 1–2 hours, with four wet diapers and four stools in
the past 24 hours. At a follow-up visit on postpartum day 20, the
infant’s weight was 4.075kg, and the mother reported nursing
14 times a day with numerous wet and soiled diapers.
At this time, the mother was planning to return to work as a
manager at a fast food restaurant within a few weeks. She
discussed with the lactation consultant that her supervisor
allowed on-the-clock smoking breaks, but she would have to
clock out to pump. As there was no private place to pump in
her workplace, she planned to express milk in her car. She
subsequently decided to defer returning to work until at least
2 months postpartum, so that she could continue to breastfeed
exclusively.
At 32 days postpartum, she presented to the emergency
department with vaginal bleeding, which was evaluated and
felt to be consistent with resumption of her menstrual cycle.
She had resumed intercourse, and her plan for Nexplanon
placement at her postpartum visit was discussed. She pre-
sented 2 days later for her postpartum visit, and reported
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having had intercourse 9 days previously. She was counseled
that early pregnancy could not be excluded at that time, and a
follow-up visit for Nexplanon placement was scheduled for 1
week later.
On postpartum day 35, the infant presented for a 1-month
well-child check, and was noted to be breastfeeding every
2 hours during the day, and every 4 hours at night. His weight
had increased to 4.600 kg.
The next week, on postpartum day 39, she had the implant
placed in the OB clinic, where it was documented that she
was exclusively breastfeeding. She was counseled regarding
possible side effects of implant placement, including ‘‘ir-
regular spotting for the full 3 years, potential difficulty in
removal, and the need to palpate the implant after placement
and intermittently over the next three years.’’
One week later, on postpartum day 46, the infant presented
to pediatrics clinic for evaluation of a rash, which was con-
sistent with neonatal acne. It was documented that he was
breastfeeding well without issues, and his weight was 4.93 kg.
The infant review of systems documented no fevers, vomit-
ing, or diarrhea.
Whenmother and infant returned to the clinic on postpartum
day 70, the infant weighed 4.785 g, down 145 g since the last
visit 24 days previously (Figure 1). The mother noted that her
milk supply had decreased, and shewas now able to pump only
1–2 oz at a time, down from 4–5 oz previously. She was
breastfeeding every 2–4 hours, usually for 10–15 minutes,
having previously breastfed for 45 minutes. She reported that
her baby was not content, and was fussy and whining more
than usual. A pre- and postweight feed was performed, and the
infant transferred 54mL. Formula supplementation was re-
commended, and the infant took 2 oz from a bottle. The review
of systems documented that there was no vomiting, diarrhea,
increased work of breathing, or sweating during feeds.
One week later, the mother and infant returned for a lac-
tation visit. She had begun taking fenugreek. She was sup-
plementing with 1–2 oz of formula after each breastfeeding,
and the infant had gained 70 g. One month later, she transi-
tioned completely to formula feeding.
Discussion
We report a case of abrupt change in growth of an exclu-
sively breastfed infant, coincident with maternal initiation of
the etonogestrel (ENG) implant. In this case, the woman
experienced a substantial decrease in her breast milk supply,
and subsequent decrease in infant growth, shortly after
starting the ENG-releasing contraceptive implant. This may
have been coincidence; however, it appears that no other
significant factors, such as returning to work or decreasing
frequency of feeding, contributed to her decrease in milk
supply.
We reported this case of lactation suppression to the FDA
Adverse Event Reporting System. To determine whether
others have reported lactation suppression in the setting of
ENG, we obtained quarterly data files from the FDA Adverse
Event Reporting System from July 2013 to June 2015.1 A
total of 1,928,561 reports were filed in this 2-year period, of
which 6,036 were related to ENG (Table 1). The most
common adverse events reported for ENG were product
quality issues (N = 701) and medical device complication
(N = 657). Among ENG reports, there were 10 cases where
breastfeeding was noted, 2 cases of lactation disorder, and no
cases of lactation suppression.
Details of the two lactation disorder reports were requested
from the FDA. Both cases were patient reports initially filed
with Merck, the manufacturer of the implant. In one case, a
patient reported experiencing a reduction in breast milk
production following placement of an ENG implant. In the
second case, a patient had an ENG implant placed immedi-
ately following an abortion. She reported that a month after
implant placement, she was still lactating and also having
some spotting.
Strengths of our case report include documentation of in-
fant weights at multiple time points, as well as documentation
of stable breastfeeding frequency over time. This is the only
case report to our knowledge of lactation suppression coin-
cident with initiation of the ENG implant.
This case raises several important issues that need to be
considered to enable women to both achieve their infant
feeding goals and adequately space future pregnancies. The
use of hormonal contraceptives in breastfeeding is contro-
versial. Progesterone withdrawal following delivery is thought
Table 1. FAERS Reports, July 2013–June 2015
Etonogestrel All reports
FAERS cases reported 6,036 1,928,561
Suppressed lactation 0 122
Lactation disorder 2 75
Breastfeeding 10 131
FAERS, FDA adverse events reporting system.
FIG. 1. Infant weight trajectory before and after place-
ment of an etonogestrel-releasing contraceptive implant,
compared with WHO growth percentiles for exclusively
breastfed male infants.
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to trigger secretory activation and onset of milk production,2
raising biologically plausible concerns that early initiation of
hormonal contraception may decrease milk supply. There is
also evidence that a subsequent pregnancy, which increases
progesterone, may affect the growth of breastfed children.
In a small study in rural Bhutan, children of women who
became pregnant again before weaning had slower growth
than age-matched children of mothers who weaned while
not pregnant.3 However, published studies have found sim-
ilar breastfeeding durations and infant weight gain among
women using hormonal versus nonhormonal contraception.
A recent Cochrane review noted that the quality of evi-
dence regarding hormonal contraception and lactation was
moderate overall and low for three of four placebo-controlled
trials.4
The contraceptive implant available in the United States
contains ENG, a synthetic progesterone analogue. Serum
levels peak at 1,200 pg/mL within the first 2 weeks after in-
sertion and then gradually decline to 202 pg/mL at 12
months.5 Based on serum and milk levels in a prospective
study of 42 mother–infant dyads, breastfed infants are ex-
pected to receive about 19.9 ng/kg of ENG daily at 1 month,
15.1 ng/kg daily at 2months, and 10.5 ng/kg daily at 4months
after insertion.6
Of note, doses, formulations, and serum levels vary among
hormonal contraceptive methods. For example, while ENG
levels decline to 202 pg/mL by 12 months after ENG implant
placement, with the extended release ENG and ethinyl es-
tradiol insert (Nuvaring), ENG levels range from 1,578 pg/
mL in week 1 to 1,374 pg/mL in week 3 of the 4-week cycle.7
Different formulations may also have different effects on
breast physiology. For example, there is evidence that for-
mulations of estrogen and progestin differentially affect breast
cell proliferation in postmenopausal women.8 These results
suggest that effects for one progestin or estrogen may not be
generalizable to other formulations.
Two recent randomized controlled trials have measured
breastfeeding outcomes among women receiving the ENG
implant. In a randomized controlled trial (RCT) comparing
early insertion (1–3 days postpartum) with standard insertion
(n = 69), there was no difference in hours to lactogenesis (mean
difference, -1.4 hours, 95% CI -10.6 to 7.7 hours) or lactation
failure (early: 1/34 vs. standard 0/35, risk difference 0.03,
95% CI -0.02 to 0.08) between the two groups.9 The study
was powered based on a baseline lactation failure rate of 5%
in both groups, with sufficient power to detect a failure rate of
20% or higher in the early placement group. There was no
difference in the percentage of women partially or com-
pletely breastfeeding at 3 or 6 months. A second small RCT
(n= 24) used deuterium to indexmilk ingestion among healthy
term newborns of mothers randomized to immediate post-
partum ENG implant placement (n= 12) or 6-week placement
(n= 12).10 Participation was limited to nonobese women who
had previously breastfed for at least 3 months. No differences
were found in milk intake between the two groups.
An open-label, randomized pilot study of 40 exclusively
breastfeeding women compared early postpartum insertion
(24–48 hours postdelivery) of the ENG implant with 6-week
postpartum DMPA administration.11 The authors found no
differences in infant growth or rates of breastfeeding between
the two groups. In the implant group (n= 20), one woman had
stopped breastfeeding exclusively by 6 weeks postpartum,
compared with three who had stopped in the group assigned to
receive DMPA at 6 weeks (n= 20). At 12 weeks postpartum,
infant growth was greater in the implant group than the DMPA
group, and rates of exclusive breastfeeding were similar (Im-
plant: 85% vs DMPA: 75%). An earlier open-label group
comparison study measured milk composition and infant
growth among 80 fully breastfeeding women and their infants.
Women chose to receive either an ENG implant (n= 42) or a
copper intrauterine device (n= 38) at 28–56 days postpar-
tum.6,12 There were no differences between group means in
24-hour milk production, fat content, or infant growth.
Combining these four studies, a total of 108 breastfeeding
women have been studied while using the ENG implant, with
one case of primary lactation failure documented in a woman
randomized to immediate postpartum ENG.9 If this case of
lactation failure were not due to chance, the estimated risk of
lactation failure with the ENG implant would be 1 case
among 108 women receiving ENG at some time between
birth and 8 weeks postpartum, or 0.9% (95% confidence in-
terval 0.2–5.1%). Of note, these four studies evaluated
healthy women with term infants; two trials excluded women
with BMI ‡30 kg/m2. The effects of the ENG implant on
lactation for women with medical problems or preterm in-
fants are not known. In addition to published trials of ENG in
lactation, we found one report of decreased milk supply
following ENG implant insertion in the FAERS database
over a 24-month period, suggesting that such adverse effects
are uncommon. However, reporting of lactation disorders or
suppressed lactation was rare in the FAERS database, and it is
possible that healthcare providers do not consider an abrupt
reduction in milk production to be a reportable adverse event.
In our clinical experience, we have found that women
receive biased information about the potential effects of
hormonal contraception on lactation. Providers focused on
preventing unplanned pregnancy may dismiss concerns as
anecdotal and insist that there is no risk, whereas providers
who are focused on breastfeeding may dwell on the risks,
dissuading women from choosing a highly effective method.
In both situations, providers’ competing priorities prevent
open communication of relevant information, undermining
patient autonomy and informed consent.13
Studies are needed to determine whether there is a causal
relationship between hormonal contraception and suppressed
lactation and, if so, whether there are identifiable risk factors
that can be used to inform counseling. Potential approaches to
advance this work include routine reporting of suppressed
lactation to FAERS, establishment of a registry of women
who experience suppressed lactation coincident with use of
hormonal contraceptives, and translational studies to mea-
sure the effect of hormonal contraception on the milk tran-
scriptome14 and on cultured lactocytes. If an adverse effect is
found, it will also be important to determine whether or not
the effect is reversible.
Until such data are available, prevailing uncertainties pose
challenges for healthcare providers counseling breastfeeding
mother–infant dyads about ENG implants. The ENG implant
is a highly effective, long-acting, reversible contraceptive
method that has much higher continuation rates than pills,
patches, or injectable contraception.15 Providers, including
the provider in our report, routinely counsel women about
potential side effects, including irregular spotting, difficult
removal, and the need to palpate the implant periodically
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after placement. In the case described here, anticipatory guid-
ance about a potential effect on milk production might
have prompted the mother to take her baby in for a weight
check earlier, preventing him from falling off his growth
curve. However, if the events we describe here are a chance
association, such counseling has the potential to unneces-
sarily dissuade women from choosing a highly effective
contraceptive method.
Available data suggest that adverse effects of ENG implants
on breast milk production are uncommon. However,more than
3 million women in the United States initiate breastfeeding
each year, suggesting that even a 1-per-1,000 risk of sup-
pressed lactation might affect a substantial number of women.
The possibility of decreased breast milk from an implant may
be qualitatively different for a woman intending to breastfeed
than the other uncommon risks the implant may pose such as
skin infection. Given uncertainty regarding the true effect of
ENG implants on lactation, it seems prudent for healthcare
providers to counsel each woman about a possible effect on
milk supply so that she can monitor her infant for signs of
impaired milk transfer. Furthermore, patient-centered coun-
seling approaches are needed that allow each woman to assess
her own individual tolerance of risk of unplanned pregnancy
versus risk of possible lactation failure. Such an approach will
ensure that each patient can make an informed decision that is
free from coercion, pressure, or undue influence.13
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